Success Metrics

Clinical Success Rate
87.5%

Based on 21 completed trials

Completion Rate
88%(21/24)
Active Trials
0(0%)
Results Posted
95%(20 trials)
Terminated
3(12%)

Phase Distribution

Ph phase_4
4
16%
Ph phase_2
2
8%
Ph phase_3
16
64%

Phase Distribution

0

Early Stage

2

Mid Stage

20

Late Stage

Phase Distribution22 total trials
Phase 2Efficacy & side effects
2(9.1%)
Phase 3Large-scale testing
16(72.7%)
Phase 4Post-market surveillance
4(18.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.0%

21 of 25 finished

Non-Completion Rate

16.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

25

all time

Status Distribution
Completed(21)
Terminated(4)

Detailed Status

Completed21
Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
25
Active
0
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (9.1%)
Phase 316 (72.7%)
Phase 44 (18.2%)

Trials by Status

completed2184%
withdrawn14%
terminated312%

Recent Activity

0 active trials
Showing 5 of 25
completedphase_3

A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis

NCT00642967
completedphase_3

A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.

NCT00717821
completedphase_4

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

NCT00773513
completed

A Study to Assess Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CKD) Participants Not in Dialysis Treated With Methoxy Polyethylene Glycol-Epoetin Beta (COMETE)

NCT01756612
completedphase_4

A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or Dialysis

NCT01519947
View all 25 trials

Clinical Trials (25)

Showing 20 of 25 trialsScroll for more
NCT00642967Phase 3

A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis

Completed
NCT00717821Phase 3

A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.

Completed
NCT00773513Phase 4

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

Completed
NCT01756612

A Study to Assess Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CKD) Participants Not in Dialysis Treated With Methoxy Polyethylene Glycol-Epoetin Beta (COMETE)

Completed
NCT01519947Phase 4

A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or Dialysis

Completed
NCT00661505Phase 3

A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia

Completed
NCT02049346Phase 4

Comparison Among Erythropoietin Stimulating Agents

Completed
NCT00717366Phase 2

Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis

Completed
NCT00642668Phase 4

A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia

Completed
NCT00737477Phase 3

A Study of Monthly Subcutaneous (SC) Mircera for Maintenance Treatment of Participants With Chronic Kidney Disease on Peritoneal Dialysis

Completed
NCT02547454

An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)

Completed
NCT02238080

An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Chronic Kidney Disease Participants on Dialysis

Completed
NCT01194154Phase 2

A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)

Completed
NCT00559273Phase 3

A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis

Completed
NCT00560547Phase 3

A Study of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.

Withdrawn
NCT00545571Phase 3

MIRACLE Study: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Participants With Chronic Renal Anemia

Completed
NCT00605293Phase 3

A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia

Completed
NCT00559637Phase 3

A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis

Completed
NCT00773968Phase 3

A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal Anemia

Completed
NCT00462384Phase 3

A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Participants With Chronic Kidney Disease.

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
25